TYK MEDICINES-B Shares Surge Nearly 5% in Afternoon Session as Key Drug Gains Priority Review Status

Stock News02-06 14:26

TYK MEDICINES-B (02410) experienced a notable increase of nearly 5% during afternoon trading. At the time of writing, the stock was up 3.65%, trading at HK$13.06, with a turnover of HK$28.91 million. The upward movement follows the company's recent announcement that its investigational Class 1 new drug, TY-9591 tablets (Edotinib Mesylate Tablets), has been included in the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) priority review list. This drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletion or exon 21 substitution mutations and present with central nervous system metastases. Inclusion in the priority review program signifies a comprehensive acceleration of the drug's evaluation process, potentially leading to an earlier market launch and providing a new treatment option for patients in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment